When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
For patients with nonmetastatic non—small cell lung cancer (NSCLC) who are at intermediate-risk of developing febrile neutropenia (FN), biosimilar filgrastim (Zarxio) is cost-effective when used as a primary prophylaxis (PP) when a payer’s willingness-to-pay (WTP) threshold is $50,000 per quality-adjusted life-year (QALY) gained, according to a new study.
Findings were presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology. Patients with nonmetastatic NSCLC are at intermediate risk (10%-20%) of developing FN if they are receiving platinum-based chemotherapy.
Authors said most patients with NSCLC who receive chemotherapy have ≥1 FN risk factors, and although PP can reduce the incidence of FN, it is more costly than secondary prophylaxis (SP).
The study used a Markov statistical model to evaluate PP versus SP to prevent chemotherapy-induced FN in patients 61 years of age receiving adjuvant carboplatin/paclitaxel every 3 weeks for 4 cycles.
Investigators conducted separate analyses for patients with 0 FN risk factors and ≥1 FN risk factors, representing 11.3% and 18% baseline FN risk, respectively. They calculated incremental cost-effectiveness ratios (ICERs) for cost per FN event avoided, life-year saved (LYS), and QALY gained from a United States payer perspective.
Cost-Effectiveness for Patients
Use of filgrastim as PP versus SP provided an additional 0.056 QALYs (0.079 LYS) for patients with 0 risk factors, at an incremental cost of $3266. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $46,815, $41,555, and $58,531, respectively.
For patients with 1 or more risk factors for FN, PP versus SP added 0.090 QALYs (0.127 LYS) at an incremental cost of $1605. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $13,970, $12,644, and $17,805, respectively.
Investigators also conducted deterministic and probabilistic sensitivity analyses, finding that the likelihood of cost-effectiveness at a WTP threshold of $50,000 per QALY gained was 31.7% for patients with 0 risk factors for FN and 96.6% for those with at least 1 FN risk factor.
Reference
Li EC, Mezzio D, Spargo K, Campbell KJ, Lyman GH. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk. Presented at ASCO20 Virtual; May 30-31, 2020. Abstract e19401
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.